The corona vaccine test, created in partnership with the American company Johnson & Johnson, produced antibodies that could protect mice from novel corona virus infection.
The trial of the Kovid-19 vaccine, developed in partnership with American multinational Johnson & Johnson, found that it produced antibodies that could protect mice from novel corona virus infection. This has been revealed in a study.
According to the study published in the journal Nature Medicine, this vaccine enhanced the strong immune system in Syrian golden mice and saved them from many diseases and deaths like pneumonia. Johnson & Johnson and Birth Israel Deaconess Medical Center (BIDMC) have used the common cold cold virus ‘Adenovirus serotype 26’ (AD26) in a jointly developed vaccine.
“We recently saw that the AD26-based SARS-COV-2 vaccine developed a robust safety system inside monkeys and is now being tested on humans,” said Dan Baruch, director of the BIDMC Center for Virology and Vaccine Research. ”
He also said, “Although monkeys do not normally have more serious illnesses, and therefore it was necessary to study whether this vaccine could protect mice from severe pneumonia and SARS-COV-2 death.”